Cargando…

RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review

Current strategies for managing craniopharyngioma result in significant morbidity. Successful treatment with interferon alfa(INFα) after progression is reported in the literature. This retrospective review details our institutional experience with INFα in craniopharyngioma patients. Method: Between...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Prabhumallikarjun, Gray, Rachel, Goldman-Yassen, Adam, Aguilera, Dolly, Castellino, Robert, Janss, Anna, Mazewski, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164804/
http://dx.doi.org/10.1093/neuonc/noac079.053
_version_ 1784720225391869952
author Patil, Prabhumallikarjun
Gray, Rachel
Goldman-Yassen, Adam
Aguilera, Dolly
Castellino, Robert
Janss, Anna
Mazewski, Claire
author_facet Patil, Prabhumallikarjun
Gray, Rachel
Goldman-Yassen, Adam
Aguilera, Dolly
Castellino, Robert
Janss, Anna
Mazewski, Claire
author_sort Patil, Prabhumallikarjun
collection PubMed
description Current strategies for managing craniopharyngioma result in significant morbidity. Successful treatment with interferon alfa(INFα) after progression is reported in the literature. This retrospective review details our institutional experience with INFα in craniopharyngioma patients. Method: Between 2000-2021, we treated 81 craniopharyngioma patients. Twenty-two patients received 26 treatment courses of subcutaneous INFα. Twenty-three courses were evaluable for response. Results: Ten patients received upfront INFα after cyst decompression +/- ommaya placement. Progression free survival(PFS) ranged between 7-38mo. Three patients continue on treatment (10+, 12+, 14+mo); seven progressed (four on treatment (7, 9, 25, 38mo), three after treatment (13, 19, 32mo)). At progression, three underwent surgery alone, three underwent surgery and radiation, one resumed INFα. Thirteen patients received INFα after progression. Prior to INFα, eight patients had had surgery, five surgery and radiation. Two in each group had INFα, previously. PFS ranged between 5-82+mo. One patient remains on treatment (5+mo); four continue in follow-up without progression (23+,40+,64+,82+mo) with two patients avoiding radiation to date; eight progressed (three on treatment (6-8mo), five after treatment (16,24,26,46,71mo)). At progression, two underwent surgery alone, three underwent surgery and radiation, one received re-irradiation, two resumed INFα. While receiving INFα, two patients experienced serious adverse events (one intra-tumoral hemorrhage (not attributed to INFα), one suicidal ideation). Both recovered. One tolerated retreatment with INFα. Three additional patients stopped INFα for intolerance, but two received INFα at subsequent progression. No other unanticipated side effects were reported. Conclusion: INFα therapy in patients with both newly diagnosed and progressive craniopharyngioma delayed the need for aggressive surgical resection and/or radiotherapy in some cases. In some patients, INFα resulted in prolonged stabilization of disease delaying or avoiding radiation. Overall, INFα side effects were manageable. These results are encouraging regarding INFα therapy for patients with craniopharyngioma and warrant further evaluation with a clinical trial.
format Online
Article
Text
id pubmed-9164804
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91648042022-06-05 RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review Patil, Prabhumallikarjun Gray, Rachel Goldman-Yassen, Adam Aguilera, Dolly Castellino, Robert Janss, Anna Mazewski, Claire Neuro Oncol Craniopharyngioma and Rare Tumors Current strategies for managing craniopharyngioma result in significant morbidity. Successful treatment with interferon alfa(INFα) after progression is reported in the literature. This retrospective review details our institutional experience with INFα in craniopharyngioma patients. Method: Between 2000-2021, we treated 81 craniopharyngioma patients. Twenty-two patients received 26 treatment courses of subcutaneous INFα. Twenty-three courses were evaluable for response. Results: Ten patients received upfront INFα after cyst decompression +/- ommaya placement. Progression free survival(PFS) ranged between 7-38mo. Three patients continue on treatment (10+, 12+, 14+mo); seven progressed (four on treatment (7, 9, 25, 38mo), three after treatment (13, 19, 32mo)). At progression, three underwent surgery alone, three underwent surgery and radiation, one resumed INFα. Thirteen patients received INFα after progression. Prior to INFα, eight patients had had surgery, five surgery and radiation. Two in each group had INFα, previously. PFS ranged between 5-82+mo. One patient remains on treatment (5+mo); four continue in follow-up without progression (23+,40+,64+,82+mo) with two patients avoiding radiation to date; eight progressed (three on treatment (6-8mo), five after treatment (16,24,26,46,71mo)). At progression, two underwent surgery alone, three underwent surgery and radiation, one received re-irradiation, two resumed INFα. While receiving INFα, two patients experienced serious adverse events (one intra-tumoral hemorrhage (not attributed to INFα), one suicidal ideation). Both recovered. One tolerated retreatment with INFα. Three additional patients stopped INFα for intolerance, but two received INFα at subsequent progression. No other unanticipated side effects were reported. Conclusion: INFα therapy in patients with both newly diagnosed and progressive craniopharyngioma delayed the need for aggressive surgical resection and/or radiotherapy in some cases. In some patients, INFα resulted in prolonged stabilization of disease delaying or avoiding radiation. Overall, INFα side effects were manageable. These results are encouraging regarding INFα therapy for patients with craniopharyngioma and warrant further evaluation with a clinical trial. Oxford University Press 2022-06-03 /pmc/articles/PMC9164804/ http://dx.doi.org/10.1093/neuonc/noac079.053 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Craniopharyngioma and Rare Tumors
Patil, Prabhumallikarjun
Gray, Rachel
Goldman-Yassen, Adam
Aguilera, Dolly
Castellino, Robert
Janss, Anna
Mazewski, Claire
RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
title RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
title_full RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
title_fullStr RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
title_full_unstemmed RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
title_short RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
title_sort rare-28. the use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
topic Craniopharyngioma and Rare Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164804/
http://dx.doi.org/10.1093/neuonc/noac079.053
work_keys_str_mv AT patilprabhumallikarjun rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview
AT grayrachel rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview
AT goldmanyassenadam rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview
AT aguileradolly rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview
AT castellinorobert rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview
AT janssanna rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview
AT mazewskiclaire rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview